Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abiomed, Inc. stock logo
ABMD
Abiomed
$381.02
$380.55
$219.85
$381.99
$17.18B1.4611,028 shs258 shs
Haemonetics Corporation stock logo
HAE
Haemonetics
$76.39
+2.4%
$68.51
$55.30
$94.99
$3.58B0.39670,689 shs724,389 shs
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
$155.96
$155.74
$93.34
$156.22
$10.30B0.55656,912 shsN/A
NovoCure Limited stock logo
NVCR
NovoCure
$17.88
+0.4%
$17.73
$14.17
$34.13
$1.98B0.721.14 million shs1.16 million shs
Penumbra, Inc. stock logo
PEN
Penumbra
$251.19
-2.1%
$271.67
$148.00
$310.00
$9.94B0.47451,810 shs518,828 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abiomed, Inc. stock logo
ABMD
Abiomed
0.00%0.00%0.00%0.00%0.00%
Haemonetics Corporation stock logo
HAE
Haemonetics
+1.08%+3.63%+10.48%+18.79%-9.62%
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
0.00%0.00%0.00%0.00%0.00%
NovoCure Limited stock logo
NVCR
NovoCure
-1.11%+7.16%-5.67%+1.60%+3.91%
Penumbra, Inc. stock logo
PEN
Penumbra
-0.04%+0.62%-4.23%-5.60%+42.25%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abiomed, Inc. stock logo
ABMD
Abiomed
1.5275 of 5 stars
0.00.00.04.30.61.71.9
Haemonetics Corporation stock logo
HAE
Haemonetics
4.8517 of 5 stars
4.52.00.04.32.11.72.5
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
N/AN/AN/AN/AN/AN/AN/AN/A
NovoCure Limited stock logo
NVCR
NovoCure
3.7767 of 5 stars
3.31.00.04.53.11.70.0
Penumbra, Inc. stock logo
PEN
Penumbra
4.7278 of 5 stars
3.43.00.03.73.42.51.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abiomed, Inc. stock logo
ABMD
Abiomed
0.00
N/AN/AN/A
Haemonetics Corporation stock logo
HAE
Haemonetics
2.91
Moderate Buy$96.8026.72% Upside
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
0.00
N/AN/AN/A
NovoCure Limited stock logo
NVCR
NovoCure
2.67
Moderate Buy$32.8383.63% Upside
Penumbra, Inc. stock logo
PEN
Penumbra
2.88
Moderate Buy$302.4020.39% Upside

Current Analyst Ratings Breakdown

Latest HRC, ABMD, PEN, NVCR, and HAE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/27/2025
NovoCure Limited stock logo
NVCR
NovoCure
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$34.00
6/26/2025
Haemonetics Corporation stock logo
HAE
Haemonetics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$87.00
6/25/2025
Haemonetics Corporation stock logo
HAE
Haemonetics
Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/20/2025
Haemonetics Corporation stock logo
HAE
Haemonetics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$100.00 ➝ $100.00
5/9/2025
Haemonetics Corporation stock logo
HAE
Haemonetics
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingStrong-Buy ➝ Strong-Buy$115.00 ➝ $105.00
5/8/2025
Haemonetics Corporation stock logo
HAE
Haemonetics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$104.00 ➝ $84.00
4/24/2025
Penumbra, Inc. stock logo
PEN
Penumbra
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$320.00 ➝ $330.00
4/24/2025
Penumbra, Inc. stock logo
PEN
Penumbra
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
4/24/2025
Penumbra, Inc. stock logo
PEN
Penumbra
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$301.00 ➝ $318.00
4/24/2025
Penumbra, Inc. stock logo
PEN
Penumbra
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$315.00 ➝ $330.00
4/24/2025
Penumbra, Inc. stock logo
PEN
Penumbra
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$315.00 ➝ $330.00
(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abiomed, Inc. stock logo
ABMD
Abiomed
$1.03B16.65$5.09 per share74.88$33.03 per share11.54
Haemonetics Corporation stock logo
HAE
Haemonetics
$1.36B2.70$7.38 per share10.35$16.34 per share4.67
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
$3.02B3.41$9.29 per share16.79$28.56 per share5.46
NovoCure Limited stock logo
NVCR
NovoCure
$605.22M3.29N/AN/A$3.33 per share5.37
Penumbra, Inc. stock logo
PEN
Penumbra
$1.19B8.14$2.83 per share88.90$29.99 per share8.38
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abiomed, Inc. stock logo
ABMD
Abiomed
$136.51M$5.8265.4769.783.3324.84%14.77%13.32%N/A
Haemonetics Corporation stock logo
HAE
Haemonetics
$167.68M$3.3123.0815.161.2112.32%26.37%9.22%8/14/2025 (Estimated)
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
$248.50M$3.7241.9221.72N/A8.23%23.07%8.96%N/A
NovoCure Limited stock logo
NVCR
NovoCure
-$168.63M-$1.51N/AN/AN/A-26.41%-45.46%-13.34%7/24/2025 (Estimated)
Penumbra, Inc. stock logo
PEN
Penumbra
$14.01M$1.06236.9750.142.293.41%11.14%8.40%7/29/2025 (Estimated)

Latest HRC, ABMD, PEN, NVCR, and HAE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/29/2025Q2 2025
Penumbra, Inc. stock logo
PEN
Penumbra
$0.81N/AN/AN/A$327.37 millionN/A
7/24/2025Q2 2025
NovoCure Limited stock logo
NVCR
NovoCure
-$0.40N/AN/AN/A$153.87 millionN/A
5/8/2025Q4 2025
Haemonetics Corporation stock logo
HAE
Haemonetics
$1.22$1.24+$0.02$1.17$329.38 million$330.60 million
4/24/2025Q1 2025
NovoCure Limited stock logo
NVCR
NovoCure
-$0.47-$0.31+$0.16-$0.31$147.57 million$154.99 million
4/23/2025Q1 2025
Penumbra, Inc. stock logo
PEN
Penumbra
$0.66$0.83+$0.17$1.00$315.72 million$324.14 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abiomed, Inc. stock logo
ABMD
Abiomed
N/AN/AN/AN/AN/A
Haemonetics Corporation stock logo
HAE
Haemonetics
N/AN/AN/AN/AN/A
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
$0.960.62%N/A25.81%N/A
NovoCure Limited stock logo
NVCR
NovoCure
N/AN/AN/AN/AN/A
Penumbra, Inc. stock logo
PEN
Penumbra
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abiomed, Inc. stock logo
ABMD
Abiomed
N/A
7.93
7.17
Haemonetics Corporation stock logo
HAE
Haemonetics
1.12
1.62
0.99
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
0.97
1.38
1.05
NovoCure Limited stock logo
NVCR
NovoCure
0.27
1.47
1.41
Penumbra, Inc. stock logo
PEN
Penumbra
0.02
6.30
3.68

Institutional Ownership

CompanyInstitutional Ownership
Abiomed, Inc. stock logo
ABMD
Abiomed
94.48%
Haemonetics Corporation stock logo
HAE
Haemonetics
99.67%
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
76.45%
NovoCure Limited stock logo
NVCR
NovoCure
84.61%
Penumbra, Inc. stock logo
PEN
Penumbra
88.88%

Insider Ownership

CompanyInsider Ownership
Abiomed, Inc. stock logo
ABMD
Abiomed
2.50%
Haemonetics Corporation stock logo
HAE
Haemonetics
1.84%
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
0.69%
NovoCure Limited stock logo
NVCR
NovoCure
5.52%
Penumbra, Inc. stock logo
PEN
Penumbra
5.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abiomed, Inc. stock logo
ABMD
Abiomed
2,00345.09 million43.96 millionOptionable
Haemonetics Corporation stock logo
HAE
Haemonetics
3,02348.04 million47.16 millionOptionable
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
10,00066.05 million65.59 millionOptionable
NovoCure Limited stock logo
NVCR
NovoCure
1,488111.49 million105.33 millionOptionable
Penumbra, Inc. stock logo
PEN
Penumbra
4,50038.73 million36.79 millionOptionable

Recent News About These Companies

Penumbra, Inc. (NYSE:PEN) CEO Sells $4,026,526.00 in Stock

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Abiomed stock logo

Abiomed NASDAQ:ABMD

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.

Haemonetics stock logo

Haemonetics NYSE:HAE

$76.39 +1.78 (+2.38%)
Closing price 03:59 PM Eastern
Extended Trading
$75.74 -0.65 (-0.85%)
As of 04:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Hill-Rom stock logo

Hill-Rom NYSE:HRC

Hill-Rom Holdings, Inc. operates as a medical technology company. The firm focuses on patient care solutions that improve clinical and economic outcomes. It operates through the following segments: Patient Support System, Front Line Care and Surgical Solutions. The Patient Support Systems segment provides bed frames and surfaces, mobility and clinical workflow solutions. The Front Line Care segment offers respiratory care products and sells medical diagnostic equipment and a diversified portfolio of devices. The Surgical Solutions segment supplies surgical products including tables, lights, pendants, positioning devices, various other surgical products and accessories. The company was founded by William A. Hillenbrand on August 7, 1969 and is headquartered in Chicago, IL.

NovoCure stock logo

NovoCure NASDAQ:NVCR

$17.88 +0.08 (+0.45%)
Closing price 04:00 PM Eastern
Extended Trading
$17.90 +0.03 (+0.14%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Penumbra stock logo

Penumbra NYSE:PEN

$251.19 -5.44 (-2.12%)
Closing price 03:59 PM Eastern
Extended Trading
$250.84 -0.34 (-0.14%)
As of 06:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.